Posts Tagged ‘Retina’
Heidelberg Makes Move into Cataract-Refractive Field
Heidelberg Engineering, which has more than 10,000 optical coherence tomography (OCT) units in place worldwide, is looking to help drive the premium channel by entering the cataract-refractive field with swept-source OCT imaging, Managing Director Kester Nahen, PhD, reported at OIS@ASCRS 2016. Heidelberg Engineering previewed its cataract and refractive imaging platform last year at the European…
Read MoreDiagnostics on the Rise
Richard Lindstrom, MD, opened up the Diagnostics-Impact on the Premium Channel with an overview of the market including a look at competitors. Video Highlights 00:37 – Global revenues in diagnostics continue to grow. 00:55 – There are 700 diagnostic products and 85 manufacturers. 01:35 – Investment in funding imaging, OCT, optical biometry and operating microscopes.…
Read MoreOutlook for Combination Therapies in Retinal Disease
When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea) and its angiopoietin2 (ANG-2) antibody, nesvacumab, it was the latest in a rash of endeavors – at least seven at last count – to marry different compounds and anti-VEGF agents…
Read MoreKOL Corner: Can Complement Inhibitors Treat Macular Degeneration?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 080″] The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field may be. Podcast Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is your…
Read MoreEye on Five – March Edition
Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and aflibercept for the treatment of wet age-related macular degeneration or diabetic macular edema. Two separate Phase II clinical studies are evaluating the combination therapy as a co-formulated, single…
Read MoreCan Apellis Find a way to Inhibit the Complement System & Treat Intermediate AMD?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 078″] Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD. 10 Top Topics in this OIS Podcast: What’s this about a Face Transplant? A successful spinout from Potentia. How…
Read MoreVisionCare Battling Back Against Macular Degeneration
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 076″] CEO Wolfgang Tolle joined VisionCare last year to move the company into the commercial stage. Now with long-term data and reimbursement in place, the firm is making a strong commercial push. Transcript Tom Salemi: Hello, OIS Podcast listeners, this is Tom Salemi, your host. Thanks for joining us today on…
Read MoreHeier Talks Anti-Angiopoietin Programs, Clinical Trials & Red Sox
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 075″] Jeff Heier, MD, is the Director of the Vitreoretinal Service and the Director of Retina Research at Ophthalmic Consultants of Boston (OCB) gives an update from the Angiogenesis conference about the advancing anti-angiopoietin programs. Podcast Guest Jeffrey Heier, MD Jeffrey S. Heier, MD is the Director of the Vitreoretinal Service…
Read MoreSecond Sight’s Argus II Shows Strong Performance at the Five-Year Mark
With news that the global market for retinal implants is expected to skyrocket to $1.1 billion by 2022, investigators of Second Sight Medical Products’ Argus II retinal implant chose a good time to report that five-year results are in line with the previously reported three-year outcomes. The results were reported at the 39th Annual Macula…
Read MoreEye on Five – February Edition 2016
The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery device market…
Read MoreApellis IPO Road Show Takes Different Route
Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the parade of biotech companies that put the brakes on planned public offerings and turned back to private equity for the capital to drive their development programs. Apellis filed last fall…
Read MoreAvalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology
How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate for age-related macular degeneration last June, Avalanche Biotechnologies has undertaken a series of significant pivots to right its ship. After releasing those results, the Menlo Park, CA, biotech company underwent…
Read More